Yamilet Zamora Padron
Payments from drug & device makers
Across 64 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$187
- Tandem Diabetes Care, Inc.$138
- Regeneron Healthcare Solutions, Inc.$122
- Mannkind Corporation$101
- Xeris Pharmaceuticals, Inc.$90
- Recordati_rare_diseases_inc.$85
- plus $536 from 15 others
What the payments were for
- Food & beverage$1,260100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $187 |
| Tandem Diabetes Care, Inc. | 8 | $138 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Mannkind Corporation | 5 | $101 |
| Xeris Pharmaceuticals, Inc. | 4 | $90 |
| Recordati_rare_diseases_inc. | 3 | $85 |
| Antares Pharma, Inc. | 4 | $75 |
| Dexcom, Inc. | 4 | $71 |
| Sanofi-aventis U.S. LLC | 2 | $68 |
| Madrigal Pharmaceuticals | 2 | $49 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Sequel Med Tech, LLC | 2 | $38 |
| Corcept Therapeutics | 2 | $37 |
| Insulet Corporation | 1 | $24 |
| BETA Bionics, Inc. | 1 | $22 |
| Acella Pharmaceuticals, LLC | 1 | $21 |
| Novartis | 1 | $21 |
| AstraZeneca | 1 | $19 |
| Beigene USA, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$122
How this compares
$1,260 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 33 | $444,201 |
| ImbruvicaIbrutinib | 17 | $258,595 |
| Abiraterone Acetate | 35 | $3,237 |
| Exemestane | 84 | $1,418 |
| Hydroxyurea | 81 | $600 |
| Imatinib Mesylate | 14 | $571 |
| Anastrozole | 98 | $524 |
| Bicalutamide | 47 | $494 |
| Dexamethasone | 41 | $220 |
| Tamoxifen Citrate | 40 | $195 |
| Prednisone | 51 | $94 |
| Letrozole | 22 | $89 |
| Ondansetron Hcl | 57 | $76 |
| Folic Acid | 39 | $47 |
| Alendronate Sodium | 18 | $35 |
Paid to pharmacies, not to this prescriber.
Other family in Miami
- Stephanie MompointMiami$4.5M
- Itsel Cardenas RamonMiami$1M
- Patrick SzarazMiami$327K
- Yamila MelendezMiami$212K
- Suzan RosenMiami$129K
- Felipe NovoaMiami$110K
- Pamela DudkiewiczMiami$89K
- Stacy FeemsterMiami$51K
- John HuffakerVenice$8M
- Miguel TrujilloMiami Gardens$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.